


Harm Reduction and SSUD



Objectives

1. Define harm reduction.
1. Define Severe Substance Use Disorder.
1. Illustrate the need for and benefits of harm reduction.
1. Identify Harm Reduction responses.

NYRA shifts resources and power to people who use drugs. We **reduce both the individual & structural harms** caused by racialized drug policy through **direct action and advocacy.**



Glossary

DSM – Diagnostic & Statistical Manual

PWID – People Who Inject Drugs

PWUD – People Who Use Drugs

SUD – Substance Use Disorders

SSUD – Severe SUD

SEP – Syringe Exchange Program

SSP – Syringe Service Program

SCS – Safe Consumption Site

OPC – Overdose Prevention Center

MOUD – Medication for Opioid Use Disorder

Why do people use drugs?

What is Harm Reduction?

Harm Reduction

- A set of practical strategies that reduce the negative consequences associated with drug use and other risk behaviors (ex: sexual risk).
- In relation to drug use it incorporates a spectrum of strategies including *safer use, managed use, abstinence*.
- Harm reduction strategies meet people "*where they're at*" (*but don't leave them there*).

**ANY
POSITIVE
CHANGE**

What Harm Reduction is

Harm reduction does not mean “anything goes.”

Harm reduction does not enable drug use or high risk behaviors.

Harm reduction does not condone, endorse, or encourage drug use.

Harm reduction does not exclude or dismiss abstinence-based treatment models as viable options.

Civil Disobedience

- SSP's
- Naloxone Distro
- SCS/OPC
- Buyer's Clubs
- Safer Supply
- Ethics & Legality




Doug Wilson

Dave Purchase handing out syringes on his own in Tacoma, Wash., in the late 1980s.
New York Times, January 27, 2013

What is SSUD?

Continuum of Use and SSUD



DSM Criteria for SUD

- 1) Opioids often taken in larger amounts/ over a longer period of time than intended.
- 2) There is a persistent desire or unsuccessful efforts to cut down or control opioid use.
- 3) A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its effects.
- 4) Craving, or a strong desire to use opioids.
- 5) Recurrent opioid use resulting in failure to fulfill major role obligations at work, school or home.
- 6) Continued opioid use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids.
- 7) Recurrent opioid use in situations in which it is physically hazardous.
- 8) Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by opioids.
- 9) Important social, occupational or recreational activities are given up or reduced because of opioid use.
- 10) *Tolerance, as defined by either of the following: (a) a need for markedly increased amounts of opioids to achieve intoxication or desired effect (b) markedly diminished effect with continued use of the same amount of an opioid
- 11) *Withdrawal, as manifested by either of the following: (a) the characteristic opioid

1, 2, 4

using “against their will,
without their permission”

3, 5, 6, 7, 8, 9

using despite negative consequences

**Punishment, Cruelty, Shame and
Do Not Work**

Current Responses to SSUD

- Punishment
- Prevention
- Treatment



Ideal Responses to SSUD

- Prevention
- Treatment
- **Harm Reduction**



The Need for Harm Redu

Traditional Drug Treatment

- Limited availability.
- People may not be ready to quit or may never choose to.
- Other reasons?
 - insurance, pregnant, health issues, rent, employment, child care, CPS, probation, drug court...*

Who Needs Harm Reduction?

80% of people with OUD are not in treatment




Who Needs Harm Reduction?

only **10.8%** who needed substance use treatment received treatment at a specialty facility in 2015.



Who Needs Harm Reduction

95.4% who classified as needing, but not receiving, substance use treatment at a specialty facility did not perceive a need for treatment.




Why Is Harm Reduction Possibly More Important Than Treatment?

“The majority of addiction resolves itself without clinical intervention by the late twenties or early thirties.”

- Higgins ST, Delaney DD, Budney AJ, Bickel WK. A behavioural approach to achieving initial cocaine abstinence. *American Journal of Psychiatry*. 1991;148:1218–1224. [[PubMed](#)] [[Google Scholar](#)]
- Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioural treatment of cocaine dependence. *Archives of General Psychiatry*. 1994;51:568–576. [[PubMed](#)] [[Google Scholar](#)]
- Higgins ST, Budney AJ, Bickel WK, Badger GJ, Foerg FE, Ogden D. Outpatient behavioural treatment for cocaine dependence. *Journal of Clinical Experimental Clinical Psychology*. 1995;23:205–212. [[Google Scholar](#)]

Harm Reduction Strategies We Have Right now

Drug, Set, Setting



Syringe Service Programs

- **80% reduction in HIV/HCV with MOUD**
- 5 x more likely to enter treatment programs
- decrease in syringe litter
- test strips/drug checking
- naloxone distro

PLUS

- tx services
- safety plans
- medical/dental
- housing services
- HIV/Hep C services
- **overdose prevention**
- Hep A + B Vaccinations
- safer sex supplies & education
- **connection, responsibility and accountability**



30+ Years of Peer-Reviewed Harm Reduction Research

1. Federal Research on Syringe Exchange Programs Proves Effectiveness Between 1991 and 1997, the US Government funded seven reports on clean needle programs for persons who inject drugs. The reports are unanimous in their conclusions that clean needle programs reduce HIV transmission, and none found that clean needle programs caused rates of drug use to increase. The federal Department of Health and Human Services currently maintains a webpage on the effectiveness of syringe exchange programs is at <http://www.amsa.gov/spp/>. Last accessed September 17, 2016. National Commission on AIDS, The Twin Epidemics of Substance Abuse and HIV (Washington DC: National Commission on AIDS, 1991). General Accounting Office, Needle Exchange Programs: Research Suggests Promise as an AIDS Prevention Strategy (Washington DC: US Government Printing Office, 1993). Laurie, P. & Reingold, A.L., et al., The Public Health Impact of Needle Exchange Programs in the United States and Abroad (San Francisco, CA: University of California, 1993). Warner, D. (ed.), How to Buy Bigger: The Clinton Administration's Policy on Needle Exchange Programs (Advisory Committee on Drug Abuse, December 10, 1993). National Research Council and Institute of Medicine (Norman, J., Ijalba, D., & Mosteller, J., eds.), Preventing HIV Transmission: The Role of Sterile Needles and Bleach (Washington DC: National Academy Press, 1995). Office of Technology Assessment, The Effectiveness of AIDS Prevention Efforts (Springfield, VA: National Technology Information Service, 1995). National Institute of Health Consensus Panel, Interventions to Prevent HIV Risk Behaviors (Kennington, MD: National Institutes of Health Consensus Program Information Center, February 1997). **2. In 1998, Donu Shalala, then Secretary of Health and Human Services in the Clinton Administration, stated:** "Ametliculous scientific review has now proven that needle exchange programs can reduce the transmission of HIV and save lives without losing ground in the battle against illegal drugs." Shalala, D.E., Secretary, Department of Health and Human Services. Press release from Department of Health and Human Services (April 20, 1998). <http://archive.hhs.gov/news/pr/1998/nps/980420a.html>. **3. NIDA Director Nora Volkow Endorses Effectiveness of Syringe Exchange in Reducing Risk of HIV Infection** "While it is not feasible to do a randomized controlled trial of the effectiveness of needer syringe exchange programs (NEPs/SEPs) in reducing HIV incidence, the majority of studies have shown that NEPs/SEPs are strongly associated with reductions in the spread of HIV when used as a component of comprehensive approach to HIV prevention. NEPs/SEPs increase the availability of sterile syringes and other injection equipment, and for exchange participants, this decreases the fraction of needles in circulation that are contaminated." This lower fraction of contaminated needles reduces the risk of injection with a contaminated needle and lowers the risk of HIV transmission. "In addition to decreasing HIV infected needles in circulation through the physical exchange of syringes, most NEPs/SEPs are part of a comprehensive HIV prevention effort that may include education on risk reduction, and referral to drug addiction treatment, job or other social services, and these interventions may be responsible for a significant part of the overall effectiveness of NEPs/SEPs. NEPs/SEPs also provide an opportunity to reach out to populations that are often difficult to engage in treatment." Nora Volkow, Director, US National Institute on Drug Abuse, correspondence with Allan Clear, "NIH Response on Harm Reduction and the Needle Exchange," Aug 4, 2004. <http://www.harmreduction.com/cslnoir/research/hiv-souderer-thouididit/hiv-nep-needs-cvpanel.com/hen-c-research/2004/09/hiv-souderer-thouididit>. **4. US Surgeon General's Determination of Effectiveness of Syringe Exchange Programs, 2011** The Surgeon General of the United States Public Health Service, VADM Regina Benjamin, MD, M.B.A., has determined that a demonstration needle exchange program (or more appropriately called syringes/serives program or SSP) would be effective in reducing drug abuse and the risk of infection with the etiologic agent for acquired immune deficiency syndrome. This determination reflects the scientific evidence supporting the important public health benefit of SSPs, and is necessary to meet the statutory requirement pertaining to the expenditure of Substance Abuse Prevention and Treatment (SAPT) Block Grant funds for SSPs. Sebelius, Kathleen, Secretary of Health and Human Services. "Determination That a Demonstration Needle Exchange Program Would be Effective in Reducing Drug Abuse and the Risk of Acquired Immune Deficiency Syndrome Infection Among Intravenous Drug Users." Federal Register, February 23, 2011, Vol. 76, No. 36, p. 10038. **Determination that a Demonstration Needle Exchange Program Would be Effective in Reducing Drug Abuse and the Risk of Acquired Immune Deficiency Syndrome Infection Among Intravenous Drug Users** <http://www.gpo.gov/fdsys/pkg/FR-2011-02-23/pdf/EFR-2011-3990.pdf>. **5. Centers for Disease Control on Syringe Exchange** The basic service offered by SSPs [Syringe Services Programs] allows PWID [People Who Inject Drugs] to exchange used needles and syringes for new, sterile needles and syringes. Providing sterile needles and syringes and establishing appropriate disposal procedures substantially reduce the chances that PWID will share injection equipment and remove potentially HIV- and HCV-contaminated syringes from the community. Many SSPs have become multiservice organizations, providing various health and social services to their participants (8). HIV and HCV testing and linkage to care and treatment for substance use disorders are among the most important of these other services. The availability of new and highly effective curative therapy for HCV infection increases the benefits of integrating testing and linkage to care among the service provided by SSPs." Don C. Des Jarlais PhD, Ann Nugent, Alisa Solberg MPA [Jonathan Felemyer MS, Jonathan Mermin MD, and Deborah Holtzman PhD. "Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas – United States, 2013," Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report (MMWR) 2015; 64: 1337-1341. <http://www.cdc.gov/mmwr/pdf/wk/mm6448a.htm> | <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6448a.htm>. **6. Participation in Syringe Exchange Program and Entry Into Drug Treatment** According to a 1997 statement by the National Institutes of Health, "Individuals in areas with needle exchange programs have an increased likelihood of entering drug treatment programs." National Institutes of Health Consensus Panel, Interventions to Prevent HIV Risk Behaviors (Kennington, MD: NIH Consensus Program Information Center, February 1997). **6. <http://www.consensus.nih.gov/1997/1997PreventHIVRiskBehaviors.htm>**. **7. US Surgeon General's Determination of Effectiveness of Syringe Exchange Programs** "After reviewing all of the research to date, the senior scientists of the Department and I have unanimously agreed that there is conclusive scientific evidence that syringe exchange programs as part of a comprehensive HIV prevention strategy, are an effective public health intervention that reduces the transmission of HIV and does not encourage the use of illegal drugs." US Surgeon General Dr. David Satcher, Department of Health and Human Services. "Evidence-Based Findings on the Efficacy of Syringe Exchange Programs: An Analysis from the Assistant Secretary for Health and Surgeon General of the Scientific Research Completed Since April 1998." (Washington DC: Dept. of Health and Human Services, February 2008). **8. Syringe Exchange Programs Work** Syringe exchange programs (SEPs) provide free sterile syringes and collect used syringes from participants. They reduce transmission of blood-borne pathogens, including human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus (HCV). "Syringe Exchange Programs – United States, 2008," Morbidity and Mortality Weekly Report (Atlanta, GA: US Centers for Disease Control, Nov. 19, 2010). Vol. 59, No. 45, 1488. <http://www.cdc.gov/mmwr/pdf/wk/mm5945a.pdf>. **Legal Access to Syringe Services** Studies on behalf of the US government conducted by the National Commission on AIDS, the University of California and the Centers for Disease Control and Prevention, the National Academy of Science, and the Office of Technology Assessment all concluded that syringe prescription and drug paraphernalia laws should be overturned or modified to allow IDUs to purchase, possess, and exchange sterile syringes. Diebert, Ryan J., MPH, Goldbaum Gary, MD, MPH, Parker, Theodore R., MPH, Hagan, Holly, PhD, Marks, Robert, MEd, Hanrahan, Michael BA, and Thiede, Hanne, DVM, MPH, "Increased Access to Unrestricted Pharmacy Sales of Syringe in Seattle-King County, Washington: Structural and Individual-Level Changes, 1996 Versus 2003," American Journal of Public Health, Vol 96, No. 8, Aug. 2006, p. 1352. <http://ajph.appublications.com/content/96/8/1347.pdf>. **9. O. Pediatrician Advocacy for Syringe & Needle Exchange** "Pediatricians should advocate for unencumbered access to sterile syringes and improved knowledge about decantamination of injection equipment. Physicians should be knowledgeable about their states' statutes regarding possession of syringes, and needles and available mechanisms for procurement. These programs should be encouraged, expanded, and linked to drug treatment and other HIV-1 risk-reduction education. It is important that these programs be conducted within the context of continuing research to document effectiveness and clarify factors that seem linked to desired outcomes." Policy Statement: Reducing the Risk of HIV Infection Associated With Illicit Drug Use. Committee on Pediatric AIDS, Pediatrics, Vol. 117, No. 2, Feb. 2006 (Chicago, IL: American Academy of Pediatrics), p. 569. <http://pediatrics.appublications.com/content/117/2/566.pdf>. **11. Services Offered by Syringe Services Programs / Syringe Exchange Programs** "Despite differences in program size operating budgets, and staffing among SSPs [Syringe Services Programs] in rural, suburban, and urban locations, there were similarities in core services (Table 3). Most SSPs offered HIV counseling and testing (107% among rural SSPs, 71% among suburban SSPs, and 90% among urban SSPs) and HCV testing (67% among rural SSPs, 79% among suburban SSPs, and 78% among urban SSPs). A minority of SSPs reported having referral tracking systems for HCV-related care and treatment (63% of rural SSPs, 43% of suburban SSPs, and 44% of urban SSPs). Rural SSPs were more likely to provide naloxone (for reversing opioid overdose) (57%) compared with suburban (57%) and urban (61%) programs that provided this service." Don C. Des Jarlais PhD, Ann Nugent, Alisa Solberg MPA, Jonathan Felemyer MS, Jonathan Mermin MD, and Deborah Holtzman PhD. "Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas – United States, 2013," Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report (MMWR) 2015; 64: 1337-1341. <http://www.cdc.gov/mmwr/pdf/wk/mm6448a.htm>. **12. Other Services Offered by SEPs** "In addition to exchanging syringes, SEPs provided various supplies, services, and referrals: in 2008, the percentage of programs providing each type of service was similar for the period 2005–2008 (Table 3). In 2008, all SEPs provided alcohol pads, and nearly all (98%) provided male condoms. Most (89%) provided referrals to substance abuse treatment. Other services also offered by SEPs included counseling and testing for HIV (87%) and HCV (65%), and screening for sexually transmitted diseases (55%) and tuberculosis (31%). Vaccinations for hepatitis A and B were provided by nearly half the programs (47% and 49%, respectively). "Syringe Exchange Programs – United States, 2008," Morbidity and Mortality Weekly Report (Atlanta, GA: Centers for Disease Control, November 19, 2010). Vol. 59, No. 45, 1489. <http://www.cdc.gov/mmwr/pdf/wk/mm5945a.pdf>. **13. OTCA Availability of Clean Syringes** "Anti-OTC laws [laws against the over-the-counter sale or purchase of syringes without prescriptions] are not associated with lower population proportions of IDUs. Laws restricting syringe access are statistically associated with HIV transmission and should be repealed. Friedman, Samuel R., PhD, Theresa Perlis PhD, and Don C. Des Jarlais PhD, "Laws Prohibiting Over-The-Counter Syringe Sales to Injection Drug Users: Relation to Population Density, HIV Prevalence, and HIV Incidence," American Journal of Public Health (Washington, DC: American Public Health Association, May 2001). Vol. 91, No. 5, p. 793. <http://ajph.appublications.com/cgi/rapidprint/91/5/791.pdf>. **14. Syringe Need and Availability** "Respondents reported injecting a median of 60 times per month, visiting the syringe exchange program a median of 4 times per month, and obtaining a median of 10 syringes per transaction; more than one in four reported reusing syringes. Fifty-four percent of participants reported receiving fewer syringes than their number of injections per month. Receiving an inadequate number of syringes was more frequently reported by younger and homeless injectors, and by those who reported public injecting in the past month. Dai, I Heller, Denise Paone, Anne Sieglar and Adam Kampati. "The syringeage: an assessment of sterile syringe need and acquisition among syringe exchange program participants in New York City," Harm Reduction Journal (London, United Kingdom; January 2009), p. 1. <http://www.harmreductionjournal.com/content/1/1/477-512>. **15. SEP Program Components** "For injecting drug users who cannot gain access to treatment or are not ready to consider it, multi-component HIV prevention programs that include sterile needle and syringe access, needles and syringes, access to drug-related HIV risk behavior, including self-reported sharing of needles and syringes, and disposal practices, and frequency of injection, needle and syringe access may include needle and syringe education, sterile needle and syringe access may include needle and syringe education (NSE) or the legal, accessible and economically affordable needles and syringes through pharmacies, voucher schemes, and physician prescription programs. Other components of multi-component HIV prevention programs may include outreach education, HIV voluntary counseling and testing, condom distribution, distribution of bleach, syringe education, and referrals to substance abuse treatment and other health and social services." Committee on the Prevention of HIV Infection among Injecting Drug Users in High-Risk Countries, Institute of Medicine, National Academy of Sciences. "Preventing HIV Infection among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence." (Washington, DC: National Academy Press, 2006), p. 175. http://www.nap.edu/openbook.php?open_book_id=11731. **Modification and Partial Lifting of the Federal Ban on Funding of Syringe Exchange Programs 201** 6'SEC. 520. Notwithstanding any other provision of this Act, no funds appropriated in this Act shall be used to purchase sterile needles or syringes for the hypodermic injection of any illegal drug. That such limitation does not apply to the use of funds for elements of a program other than making such purchases if the relevant State or local health department, in consultation with the Centers for Disease Control and Prevention, determines that the State or local jurisdiction, as applicable, is experimenting, or is at risk for, a significant increase in hepatitis infections or an HIV outbreak due to injection drug use, and such program is operating in accordance with State and local law. HR 2029, "Consolidated Appropriations Act, 2016," Passed by 114th Congress and Signed into Law on December 18, 2015. <https://www.congress.gov/bills/114/change-house-bill/2029/text> <https://www.congress.gov/114/bills/2029/HR-2029/114-bill-2029/enr/16>. **Laws Restricting Syringe Availability** "Programs that provide access to sterile syringes have been proven time and again to reduce HIV transmission without either encouraging drug use or increasing drug related crime. Syringe exchange, as well as similar measures such as nonprescription pharmacies sale of syringes, is an effective and life-saving health intervention. Yet syringe exchange is banned in much of the United States, and where it is allowed, is obstructed by laws forbidding the possession of drug paraphernalia. Other modes of syringe access such as nonprescription pharmacies sale of syringes are as of this writing forbidden in five states: California, Massachusetts, New Jersey, Delaware, and Pennsylvania. Almost all fifty states have enacted drug paraphernalia laws similar to model legislation written by the Drug Enforcement Agency in 1979 under President Jimmy Carter. Drug paraphernalia laws are encouraged by United Nations anti-drug conventions which call on governments to take aggressive law enforcement measures against "illicit drug use." Human Rights Watch, "Injecting," Reason: Human Rights and HIV Prevention for Injection Drug Users." (September 2003). <http://www.hrw.org/news/2003/09/02/human-rights-and-hiv-prevention-for-injection-drug-users>. **17. Recommendation of British Syringe Coalition on Misuse of Drugs** "Recommendation of British Syringe Coalition on Misuse of Drugs." <http://www.britishsyringe.org.uk/files/2008/02/2008020201.pdf>. **18. Recommendation of British Syringe Coalition on Misuse of Drugs** "Recommendation of British Syringe Coalition on Misuse of Drugs." <http://www.britishsyringe.org.uk/files/2008/02/2008020201.pdf>. **19. Primary Prevention of Hepatitis C Among Injecting Drug Users** (London, United Kingdom: February 2009), p. 28. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/191044/cmhdenr-report-2.pdf. **18. Syringe Access Through Pharmacies** The purchase of syringes through pharmacies may be a major source of contact with the health service for some injectors, and the potential to exploit this contact point as a conduit to other services clearly exists. Work to motivate and support pharmacists to develop the services they offer to drug users could form an important part of extending the role of pharmacies, but to date only France, Portugal and the United Kingdom appear to be making significant investments in this direction." "Annual Report 2006: The State of the Drugs Problem in Europe," European Monitoring Centre for Drugs and Drug Addiction (Luxembourg, Centre for Official Publications of the European Communities, 2006), p. 79. http://www.emcdda.europa.eu/assets/docs/enr/37244_enr2006-en.pdf. **19. Legality of Syringe Possession** According to a study in 1996, "Drug paraphernalia laws in 47 US states make it illegal for injection drug users (IDUs) to possess syringes." The study concludes, "decriminalizing syringes and needles would likely result in reductions in the behaviors that expose IDUs to blood-borne viruses." Bluthenthal, R. C., N., Kral, A. E., Bringer, Elizabeth A., and Edlin, Brian R., "Drug paraphernalia laws and injection-related infectious-disease risk among drug injectors," Journal of Drug Issues, 1999; 29(1): 1-16. Abstract available on the web at http://www.naspon.org/NASPN_ILResearch/ILPharmacyAccessToSterileSyringes20.SyringeAccessThroughPharmacies. Although most US states have legal restrictions on the sale and possession of syringes, pharmaceutical practice guidelines often allow pharmacists discretion in syringe sales decisions; this may lead to wide variation in syringe sales by individual pharmacies and to discrimination based on gender, age, race, ethnicity, or socioeconomic status. Individual-level factors associated with pharmacists' relative willingness to sell syringes include familiarity with customers; concerns about deception, disease transmission, improperly discarded syringes, and staff and customer safety; business concerns, including fear of theft and harassment of other customers by IDU patrons; and fear of increased drug use because of easier syringe access. Diebert, Ryan J., MPH, Goldbaum, Gary, MD, MPH, Parker, Theodore R., MPH, Hagan, Holly, PhD, Marks, Robert, MEd, Hanrahan, Michael BA, and Thiede, Hanne, DVM, MPH, "Increased Access to Unrestricted Pharmacy Sales of Syringe in Seattle-King County, Washington: Structural and Individual-Level Changes, 1996 Versus 2003," American Journal of Public Health, Vol. 96, No. 8, Aug. 2006, p. 1347. <http://ajph.appublications.com/cgi/rapidprint/96/8/1347.pdf>. **2. Over The Counter Syringe Availability** "The data in this report offer no support for the idea that anti-OTC laws prevent HIV drug injection. However, the data do show associations between anti-OTC laws and HIV prevalence and incidence. In an ongoing epidemic of a fatal infectious disease, prudent public health policy suggests removing prescription requirements, rather than awaiting definitive proof of association. Such action has been taken by Massachusetts, by Maryland, and recently by New York. After Connecticut legalizes OTC sales of syringes and the personal possession of syringes, syringe sharing and injection-related deaths, or arrests, or need for injection to police officers." Friedman, Samuel R., PhD, Theresa Perlis, PhD, and Don C. Des Jarlais, PhD, "Laws Prohibiting Over-the-Counter Syringe Sales to Injection Drug Users: Relation to Population Density, HIV Prevalence, and HIV Incidence," American Journal of Public Health (Washington, DC: American Public Health Association, May 2001). Vol. 91, No. 5, p. 793. <http://ajph.appublications.com/cgi/rapidprint/91/5/791.pdf>. **22. SEP and HIV Prevention** "Access to sterile needles and syringes is an important, eventual, component of a comprehensive HIV prevention program for IDUs. The data on needle exchange in the United States are consistent with the conclusion that these programs do not encourage drug use and that needle exchanges can be effective in reducing HIV incidence. Other data show that NEPs help people stop drug use through referral to drug treatment programs. The studies outside of the United States are important for reminding us that unintended consequences can occur. While changes in needle prescription and possession laws and regulations have shown promise, the identification of organizational components that improve or hinder effectiveness of needle exchange and pharmacy-based access care need monitoring." Vlahov, David, PhD, and Benjamin Jenney, MHS, "The Role of Needle Exchange Programs in HIV Prevention," Public Health Reports Volume 113, Supplement 1, June 1998, p. 79. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1307729/pdf/pubhealthreport00030079.pdf>. **23. SEPs and HIV** A literature review in 2004 by the European Union's drug monitoring agency, the European Monitoring Centre on Drugs and Drug Addiction, found that "Major reviews (summarised in Vlahov and June, 1998; Bastos and Strathdee, 2000; Ferriani, 2000) suggest that NSPs (Needle and Syringe Programs) may reduce rates of seroconversion to HIV and hepatitis by one third or more, without negative side effects on the number of IDUs (Vlahov and June, 1998). A landmark study from Hurley et al. combined HIV seroprevalence data from 81 cities with (n=52) or without (n=29) NSPs (Hurley et al., 1997). They showed that the average annual seroprevalence was 11% lower in cities with an NSP than in cities without an NSP, providing important evidence on the effectiveness of NSPs in reducing the spread of HIV." De Wit, Arndt and Jasper Bos. "Cost-Effectiveness of Needle and Syringe Programmes: A Review of the Literature." In Hepatitis C: Infecting Drug Use Impact, Costs and Policy Options, Johannes Wager, Willem Limburg, Mirjam Kreteindiner, Maarten Postma, and Lucie Weesing (eds.), European Monitoring Centre on Drugs and Drug Addition, 2004. **24. SEP and HIV** "We found that in cities with NEPs HIV seroprevalence among injecting drug users decreased over time, whereas in cities without NEPs HIV seroprevalence increased. A plausible explanation for this evidence is that the NEPs led to a reduction in HIV incidence because injecting drug users had access to clean needles and syringes." De Wit, Arndt and Jasper Bos. "Cost-Effectiveness of Needle and Syringe Programmes: A Review of the Literature." In Hepatitis C: Infecting Drug Use Impact, Costs and Policy Options, Johannes Wager, Willem Limburg, Mirjam Kreteindiner, Maarten Postma, and Lucie Weesing (eds.), European Monitoring Centre on Drugs and Drug Addition, 2004. **25. NEPs and HIV** "Needles available for reuse, as well as indirectly through activities such as bleed distribution, referrals to drug treatment centres, and other means, and education about risk behaviour. Although these mechanisms have strong theoretical support, the published evidence for NEP effectiveness is limited. Previous studies of the effect of NEPs on HIV incidence used observational designs or statistical models." Observational designs included case studies, cross-sectional, serial cross-sectional, and cohort studies (often without comparison groups); and case-control studies. **45. Only one study assessed the impact of NEPs on HIV incidence.** Des Jarlais and Colagues⁷ estimated that the hazard for incident HIV infection was 3.3 for injecting drug users in four high-seroprevalence cities without NEPs, compared with continuous users of NEPs in New York City. One case study investigated HIV prevention activities for five cities with low seroprevalence, but did not formally compare these with other cities that had high seroprevalence. **13. The most frequently cited statistical model for assessment of NEP effectiveness was developed by the New Haven NEP evaluators, and is based on the theory that NEPs decrease HIV transmission rates by lowering the time that needles are in circulation.**" The conclusion of a 1993 review by a University of California team⁷ was that NEPs are associated with decreased HIV drug risk behaviour and are not associated with negative outcomes, but that there is no clear evidence that they decrease HIV infection rates. Few new data were available for the most recent US review by the Panel on Needle Exchange and Bleach Distribution Programs, 4 which concluded that NEPs are effective, but acknowledged that the evidence was weak: "Our study is distinguished from previous work by its worldwide scope and its design, which compares changes in HIV seroprevalence in cities with and without NEPs, rather than changes within a single city." Hurley, Susan E., Damien J., Jolley, John M., Kadar. "Effectiveness of Needle-Exchange Programmes for Prevention of HIV Infection." The Lancet, 1997; 349: 1797-1800, June 21, 1997. http://www.duedhjournal.net/dedhler/MSDC/effectiveness_of_neps_for_prevention25.SyringeAccess,LimitsandInfectionRisk "In multivariate analyses we found that polysubstance use was associated independently with residing in the area with no legal possession of syringes; among SEP users, those with access to SEPs without limited low syringe re-use but not low syringe sharing; and that among non-SEP users, no significant differences in injection risk were observed among IDUs with and without pharmacy access." Conclusion: We found that greater legal access to syringes, if accompanied by limits on the number of syringes that can be exchanged, purchased and possessed, may not have the intended impacts on injection-related infectious disease risk among IDUs." Source: Bluthenthal, R. C., N., Kral, A. E., Bringer, Elizabeth A., and Edlin, Brian R., "Drug paraphernalia laws and injection-related infectious-disease risk among drug injectors," Journal of Drug Issues, 1999; 29(1): 1-16. Abstract available on the web at http://www.naspon.org/NASPN_ILResearch/ILPharmacyAccessToSterileSyringes20.SyringeAccessThroughPharmacies. The purchase of syringes through pharmacies may be a major source of contact with the health service for some injectors, and the potential to exploit this contact point as a conduit to other services clearly exists. Work to motivate and support pharmacists to develop the services they offer to drug users could form an important part of extending the role of pharmacies, but to date only France, Portugal and the United Kingdom appear to be making significant investments in this direction." "Annual Report 2006: The State of the Drugs Problem in Europe," European Monitoring Centre for Drugs and Drug Addiction (Luxembourg, Centre for Official Publications of the European Communities, 2006), p. 79. http://www.emcdda.europa.eu/assets/docs/enr/37244_enr2006-en.pdf. **19. Legality of Syringe Possession** According to a study in 1996, "Drug paraphernalia laws in 47 US states make it illegal for injection drug users (IDUs) to possess syringes." The study concludes, "decriminalizing syringes and needles would likely result in reductions in the behaviors that expose IDUs to blood-borne viruses." Bluthenthal, R. C., N., Kral, A. E., Bringer, Elizabeth A., and Edlin, Brian R., "Drug paraphernalia laws and injection-related infectious-disease risk among drug injectors," Journal of Drug Issues, 1999; 29(1): 1-16. Abstract available on the web at http://www.naspon.org/NASPN_ILResearch/ILPharmacyAccessToSterileSyringes20.SyringeAccessThroughPharmacies. Although most US states have legal restrictions on the sale and possession of syringes, pharmaceutical practice guidelines often allow pharmacists discretion in syringe sales decisions; this may lead to wide variation in syringe sales by individual pharmacies and to discrimination based on gender, age, race, ethnicity, or socioeconomic status. Individual-level factors associated with pharmacists' relative willingness to sell syringes include familiarity with customers; concerns about deception, disease transmission, improperly discarded syringes, and staff and customer safety; business concerns, including fear of theft and harassment of other customers by IDU patrons; and fear of increased drug use because of easier syringe access. Diebert, Ryan J., MPH, Goldbaum, Gary, MD, MPH, Parker, Theodore R., MPH, Hagan, Holly, PhD, Marks, Robert, MEd, Hanrahan, Michael BA, and Thiede, Hanne, DVM, MPH, "Increased Access to Unrestricted Pharmacy Sales of Syringe in Seattle-King County, Washington: Structural and Individual-Level Changes, 1996 Versus 2003," American Journal of Public Health, Vol. 96, No. 8, Aug. 2006, p. 1347. <http://ajph.appublications.com/cgi/rapidprint/96/8/1347.pdf>. **2. Over The Counter Syringe Availability** "The data in this report offer no support for the idea that anti-OTC laws prevent HIV drug injection. However, the data do show associations between anti-OTC laws and HIV prevalence and incidence. In an ongoing epidemic of a fatal infectious disease, prudent public health policy suggests removing prescription requirements, rather than awaiting definitive proof of association. Such action has been taken by Massachusetts, by Maryland, and recently by New York. After Connecticut legalizes OTC sales of syringes and the personal possession of syringes, syringe sharing and injection-related deaths, or arrests, or need for injection to police officers." Friedman, Samuel R., PhD, Theresa Perlis, PhD, and Don C. Des Jarlais, PhD, "Laws Prohibiting Over-the-Counter Syringe Sales to Injection Drug Users: Relation to Population Density, HIV Prevalence, and HIV Incidence," American Journal of Public Health (Washington, DC: American Public Health Association, May 2001). Vol. 91, No. 5, p. 793. <http://ajph.appublications.com/cgi/rapidprint/91/5/791.pdf>. **22. SEP and HIV Prevention** "Access to sterile needles and syringes is an important, eventual, component of a comprehensive HIV prevention program for IDUs. The data on needle exchange in the United States are consistent with the conclusion that these programs do not encourage drug use and that needle exchanges can be effective in reducing HIV incidence. Other data show that NEPs help people stop drug use through referral to drug treatment programs. The studies outside of the United States are important for reminding us that unintended consequences can occur. While changes in needle prescription and possession laws and regulations have shown promise, the identification of organizational components that improve or hinder effectiveness of needle exchange and pharmacy-based access care need monitoring." Vlahov, David, PhD, and Benjamin Jenney, MHS, "The Role of Needle Exchange Programs in HIV Prevention," Public Health Reports Volume 113, Supplement 1, June 1998, p. 79. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1307729/pdf/pubhealthreport00030079.pdf>. **23. SEPs and HIV** A literature review in 2004 by the European Union's drug monitoring agency, the European Monitoring Centre on Drugs and Drug Addiction, found that "Major reviews (summarised in Vlahov and June, 1998; Bastos and Strathdee, 2000; Ferriani, 2000) suggest that NSPs (Needle and Syringe Programs) may reduce rates of seroconversion to HIV and hepatitis by one third or more, without negative side effects on the number of IDUs (Vlahov and June, 1998). A landmark study from Hurley et al. combined HIV seroprevalence data from 81 cities with (n=52) or without (n=29) NSPs (Hurley et al., 1997). They showed that the average annual seroprevalence was 11% lower in cities with an NSP than in cities without an NSP, providing important evidence on the effectiveness of NSPs in reducing the spread of HIV." De Wit, Arndt and Jasper Bos. "Cost-Effectiveness of Needle and Syringe Programmes: A Review of the Literature." In Hepatitis C: Infecting Drug Use Impact, Costs and Policy Options, Johannes Wager, Willem Limburg, Mirjam Kreteindiner, Maarten Postma, and Lucie Weesing (eds.), European Monitoring Centre on Drugs and Drug Addition, 2004. **24. SEP and HIV** "We found that in cities with NEPs HIV seroprevalence among injecting drug users decreased over time, whereas in cities without NEPs HIV seroprevalence increased. A plausible explanation for this evidence is that the NEPs led to a reduction in HIV incidence because injecting drug users had access to clean needles and syringes." De Wit, Arndt and Jasper Bos. "Cost-Effectiveness of Needle and Syringe Programmes: A Review of the Literature." In Hepatitis C: Infecting Drug Use Impact, Costs and Policy Options, Johannes Wager, Willem Limburg, Mirjam Kreteindiner, Maarten Postma, and Lucie Weesing (eds.), European Monitoring Centre on Drugs and Drug Addition, 2004. **25. NEPs and HIV** "Needles available for reuse, as well as indirectly through activities such as bleed distribution, referrals to drug treatment centres, and other means, and education about risk behaviour. Although these mechanisms have strong theoretical support, the published evidence for NEP effectiveness is limited. Previous studies of the effect of NEPs on HIV incidence used observational designs or statistical models." Observational designs included case studies, cross-sectional, serial cross-sectional, and cohort studies (often without comparison groups); and case-control studies. **45. Only one study assessed the impact of NEPs on HIV incidence.** Des Jarlais and Colagues⁷ estimated that the hazard for incident HIV infection was 3.3 for injecting drug users in four high-seroprevalence cities without NEPs, compared with continuous users of NEPs in New York City. One case study investigated HIV prevention activities for five cities with low seroprevalence, but did not formally compare these with other cities that had high seroprevalence. **13. The most frequently cited statistical model for assessment of NEP effectiveness was developed by the New Haven NEP evaluators, and is based on the theory that NEPs decrease HIV transmission rates by lowering the time that needles are in circulation.**" The conclusion of a 1993 review by a University of California team⁷ was that NEPs are associated with decreased HIV drug risk behaviour and are not associated with negative outcomes, but that there is no clear evidence that they decrease HIV infection rates. Few new data were available for the most recent US review by the Panel on Needle Exchange and Bleach Distribution Programs, 4 which concluded that NEPs are effective, but acknowledged that the evidence was weak: "Our study is distinguished from previous work by its worldwide scope and its design, which compares changes in HIV seroprevalence in cities with and without NEPs, rather than changes within a single city." Hurley, Susan E., Damien J., Jolley, John M., Kadar. "Effectiveness of Needle-Exchange Programmes for Prevention of HIV Infection." The Lancet, 1997; 349: 1797-1800, June 21, 1997. http://www.duedhjournal.net/dedhler/MSDC/effectiveness_of_neps_for_prevention25.SyringeAccess,LimitsandInfectionRisk "In multivariate analyses we found that polysubstance use was associated independently with residing in the area with no legal possession of syringes; among SEP users, those with access to SEPs without limited low syringe re-use but not low syringe sharing; and that among non-SEP users, no significant differences in injection risk were observed among IDUs with and without pharmacy access." Conclusion: We found that greater legal access to syringes, if accompanied by limits on the number of syringes that can be exchanged, purchased and possessed, may not have the intended impacts on injection-related infectious disease risk among IDUs." Source: Bluthenthal, R. C., N., Kral, A. E., Bringer, Elizabeth A., and Edlin, Brian R., "Drug paraphernalia laws and injection-related infectious-disease risk among drug injectors," Journal of Drug Issues, 1999; 29(1): 1-16. Abstract available on the web at http://www.naspon.org/NASPN_ILResearch/ILPharmacyAccessToSterileSyringes20.SyringeAccessThroughPharmacies. The purchase of syringes through pharmacies may be a major source of contact with the health service for some injectors, and the potential to exploit this contact point as a conduit to other services clearly exists. Work to motivate and support pharmacists to develop the services they offer to drug users could form an important part of extending the role of pharmacies, but to date only France, Portugal and the United Kingdom appear to be making significant investments in this direction." "Annual Report 2006: The State of the Drugs Problem in Europe," European Monitoring Centre for Drugs and Drug Addiction (Luxembourg, Centre for Official Publications of the European Communities, 2006), p. 79. http://www.emcdda.europa.eu/assets/docs/enr/37244_enr2006-en.pdf. **19. Legality of Syringe Possession** According to a study in 1996, "Drug paraphernalia laws in 47 US states make it illegal for injection drug users (IDUs) to possess syringes." The study concludes, "decriminalizing syringes and needles would likely result in reductions in the behaviors that expose IDUs to blood-borne viruses." Bluthenthal, R. C., N., Kral, A. E., Bringer, Elizabeth A., and Edlin, Brian R., "Drug paraphernalia laws and injection-related infectious-disease risk among drug injectors," Journal of Drug Issues, 1999; 29(1): 1-16. Abstract available on the web at http://www.naspon.org/NASPN_ILResearch/ILPharmacyAccessToSterileSyringes20.SyringeAccessThroughPharmacies. Although most US states have legal restrictions on the sale and possession of syringes, pharmaceutical practice guidelines often allow pharmacists discretion in syringe sales decisions; this may lead to wide variation in syringe sales by individual pharmacies and to discrimination based on gender, age, race, ethnicity, or socioeconomic status. Individual-level factors associated with pharmacists' relative willingness to sell syringes include familiarity with customers; concerns about deception, disease transmission, improperly discarded syringes, and staff and customer safety; business concerns, including fear of theft and harassment of other customers by IDU patrons; and fear of increased drug use because of easier syringe access. Diebert, Ryan J., MPH, Goldbaum, Gary, MD, MPH, Parker, Theodore R., MPH, Hagan, Holly, PhD, Marks, Robert, MEd, Hanrahan, Michael BA, and Thiede, Hanne, DVM, MPH, "Increased Access to Unrestricted Pharmacy Sales of Syringe in Seattle-King County, Washington: Structural and Individual-Level Changes, 1996 Versus 2003," American Journal of Public Health, Vol. 96, No. 8, Aug. 2006, p. 1347. <http://ajph.appublications.com/cgi/rapidprint/96/8/1347.pdf>. **2. Over The Counter Syringe Availability** "The data in this report offer no support for the idea that anti-OTC laws prevent HIV drug injection. However, the data do show associations between anti-OTC laws and HIV prevalence and incidence. In an ongoing epidemic of a fatal infectious disease, prudent public health policy suggests removing prescription requirements, rather than awaiting definitive proof of association. Such action has been taken by Massachusetts, by Maryland, and recently by New York. After Connecticut legalizes OTC sales of syringes and the personal possession of syringes, syringe sharing and injection-related deaths, or arrests, or need for injection to police officers." Friedman, Samuel R., PhD, Theresa Perlis, PhD, and Don C. Des Jarlais, PhD, "Laws Prohibiting Over-the-Counter Syringe Sales to Injection Drug Users: Relation to Population Density, HIV Prevalence, and HIV Incidence," American Journal of Public Health (Washington, DC: American Public Health Association, May 2001). Vol. 91, No. 5, p. 793. <http://ajph.appublications.com/cgi/rapidprint/91/5/791.pdf>. **22. SEP and HIV Prevention** "Access to sterile needles and syringes is an important, eventual, component of a comprehensive HIV prevention program for IDUs. The data on needle exchange in the United States are consistent with the conclusion that these programs do not encourage drug use and that needle exchanges can be effective in reducing HIV incidence. Other data show that NEPs help people stop drug use through referral to drug treatment programs. The studies outside of the United States are important for reminding us that unintended consequences can occur. While changes in needle prescription and possession laws and regulations have shown promise, the identification of organizational components that improve or hinder effectiveness of needle exchange and pharmacy-based access care need monitoring." Vlahov, David, PhD, and Benjamin Jenney, MHS, "The Role of Needle Exchange Programs in HIV Prevention," Public Health Reports Volume 113, Supplement 1, June 1998, p. 79. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1307729/pdf/pubhealthreport00030079.pdf>. **23. SEPs and HIV** A literature review in 2004 by the European Union's drug monitoring agency, the European Monitoring Centre on Drugs and Drug Addiction, found that "Major reviews (summarised in Vlahov and June, 1998; Bastos and Strathdee, 2000; Ferriani, 2000) suggest that NSPs (Needle and Syringe Programs) may reduce rates of seroconversion to HIV and hepatitis by one third or more, without negative side effects on the number of IDUs (Vlahov and June, 1998). A landmark study from Hurley et al. combined HIV seroprevalence data from 81 cities with (n=52) or without (n=29) NSPs (Hurley et al., 1997). They showed that the average annual seroprevalence was 11% lower in cities with an NSP than in cities without an NSP, providing important evidence on the effectiveness of NSPs in reducing the spread of HIV." De Wit, Arndt and Jasper Bos. "Cost-Effectiveness of Needle and Syringe Programmes: A Review of the Literature." In Hepatitis C: Infecting Drug Use Impact, Costs and Policy Options, Johannes Wager, Willem Limburg, Mirjam Kreteindiner, Maarten Postma, and Lucie Weesing (eds.), European Monitoring Centre on Drugs and Drug Addition, 2004. **24. SEP and HIV** "We found that in cities with NEPs HIV seroprevalence among injecting drug users decreased over time, whereas in cities without NEPs HIV seroprevalence increased. A plausible explanation for this evidence is that the NEPs led to a reduction in HIV incidence because injecting drug users had access to clean needles and syringes." De Wit, Arndt and Jasper Bos. "Cost-Effectiveness of Needle and Syringe Programmes: A Review of the Literature." In Hepatitis C: Infecting Drug Use Impact, Costs and Policy Options, Johannes Wager, Willem Limburg, Mirjam Kreteindiner, Maarten Postma, and Lucie Weesing (eds.), European Monitoring Centre on Drugs and Drug Addition, 2004. **25. NEPs and HIV** "Needles available for reuse, as well as indirectly through activities such as bleed distribution, referrals to drug treatment centres, and other means, and education about risk behaviour. Although these mechanisms have strong theoretical support, the published evidence for NEP effectiveness is limited. Previous studies of the effect of NEPs on HIV incidence used observational designs or statistical models." Observational designs included

Harm Reduction Strategies We Need


Overdose Prevention Centers



- Increased access to drug treatment
- Reduced HIV and hepatitis C risk behavior
- Reduced the prevalence and harms of bacterial infections.
- Successfully managing overdoses
- Cost savings resulting from reduced disease, overdoses, and need for emergency medical services, and increased preventative health care and drug treatment utilizations.+

Drug Testing / Safe Supply

- People are dying from adulterated drug supply
- Reagent testing and test strips are not enough
- Quantity and quality of drugs can be tested using FTIR or Mass Spec
- Urban Survivors Union/UNC



PreArrest Diversion Programs

Housing and Poverty Programs

Punishment funding Transfer

Decriminalization Portugal **PreArrest Diversion Programs**



Housing and Poverty Programs

Punishment funding Transfer

Expand Access to Medication for Opioid

- Methadone and buprenorphine are the gold standard for OUD
- Pharmacy based methadone
- Removes criminality
- Continue telehealth induction for buprenorphine
- 80% reduction in HIV/HCV with SSP
- Get the DEA out of health care and SUD tx

On demand Treatment

- choice of treatment in 24 hours or less

Safe Drug Supply

- DULF
- Decriminalization



LOVE

What you can Do Now

Ally and Provider Tips

Avoid becoming a rescuer.

Avoid taking it personally.

Avoid the assumption they have the same goals as the person using drugs.

Be aware of recapitulated ideas of recovery.

Avoid manipulating, punishing or coercing PWUD

Ally and Provider Tips

- Do** advocate to expand harm reduction services
- Do** say they don't know when they don't know.
- Do** take risks and work around the system to meet needs.
- Do** set limits and boundaries.
- Do** treat patients as complex individuals
- Do** hold colleagues accountable for poor patient care.
- Do** celebrate Any Positive Change.

any positive change

rather than measuring success solely by
abstinence from drug use, the primary
effectiveness should be the reduction of
harm and Recovery should emphasize:

overdose death Prevention

Reduced problematic drug use

Reduced incarceration

addressing housing, poverty and Mental

Improved Health

Connection and Education



additional resources

- NY Recovery Alliance nyrecoveryalliance.org
- Next Distro nextdistro.org
- Harm Reduction Coalition harmreduction.org
- Drug Policy Alliance drugpolicy.org
- Chicago Recovery Alliance anypositivechange.org
- Sonoran Prevention Works spwaz.org
- People's Harm Reduction Alliance phra.org
- Urban Survivors Union ncurbansurvivorunion.org
- Erowid erowid.org
- Indiana Recovery Alliance indianarecoveryalliance.org
- SWRA southwestrecoveryalliance.org
- Harm Reduction Action Center harmreductionactioncenter.org

BONUS:

Is it Harm Reduction?

Principles of Harm Reduction

(1) Focus on Health and Dignity

Establishes **quality of individual and community life and well-being** as the criteria for successful interventions and policies.




(2) Participatory Centered Service

Non-judgmental and **non-coercive** provision of services and resources.

3) Participant Involvement

Ensures people have a **real voice in the creation of programs & policies** designed to serve them.



(4) Participant Autonomy

Affirms people who use drugs themselves as their own **primary agents of change**.

5) Sociocultural Factors

Recognizes various **social inequalities** affect both people's **vulnerability** and **capacity to effectively deal with potential harm**.



6) Pragmatism and Realism

Does **not** attempt to minimize or ignore the **real and tragic harm and danger** associated with licit and illicit drug use or other risk behaviors.